TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10093319

Group type: EXPERIMENTAL
Intervention: New transit work regimens at Nadymgazprom Enterprise
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Psychological status assessment using the method of Taylor
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biological rhythms, chemical control of ventilation, O2 and CO2 consumption, body temperature, hormone‐metabolic data
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Compensatory processes
Number of subjects: 240
Study: 8058229

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/day of oral elemental calcium)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 2512104

Group type: EXPERIMENTAL
Intervention: Phenobarbital administered by primary health care workers trained by a three-day course in community 'A'
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phenobarbital administered by neurologists in community 'B'
Number of subjects: 40
Study: 1113762

Group type: EXPERIMENTAL
Intervention: 125I fibrinogen count scanning
Number of subjects: 83

Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 83
Study: 31794952

Group type: EXPERIMENTAL
Intervention: VSI Patient Education (VSI PE) using HoloLens® glasses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rubber brain model (3B Scientific®)
Number of subjects: 17
Study: 31204254

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (regional anesthesia)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham blocks with saline (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with electrostimulation
Number of subjects: 20
Study: 28685353

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a 125 mcg
Number of subjects: 1512
Study: 25381447

Group type: EXPERIMENTAL
Intervention: Monolingual treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bilingual treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: No-treatment (delayed-treatment)
Number of subjects: 29
Study: 22922803

Group type: EXPERIMENTAL
Intervention: Low-load resistance training (LLRT) with blood flow restriction (BFR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-load resistance training (LLRT) without blood flow restriction (BFR)
Number of subjects: 7
Study: 21258893

Group type: EXPERIMENTAL
Intervention: Proscar combined with Aike Mixture (AKM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proscar only (Control)
Number of subjects: 60
Study: 19092669

Group type: EXPERIMENTAL
Intervention: Resting Heart system
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MECC system
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PRECiSe system
Number of subjects: 93

Group type: COMPARATOR
Intervention: cECC (HL30 Maquet)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study: 16777684

Group type: EXPERIMENTAL
Intervention: Patients with advanced NSCLC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 50
Study: 16019861

Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Post-operative follow-up (Group B)
Number of subjects: 40
Study: 12496532

Group type: EXPERIMENTAL
Intervention: Endoscopic palliation
Number of subjects: 297

Group type: COMPARATOR
Intervention: Surgical palliation
Number of subjects: 297

Group type: COMPARATOR
Intervention: Laparoscopic staging
Number of subjects: 297

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 297
Study: 10522998

Group type: EXPERIMENTAL
Intervention: 3.75 mg triptorelin im every 4 weeks for 2 years (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (n = 10)
Number of subjects: 30
Study: 7730651

Group type: EXPERIMENTAL
Intervention: IL-10 (1, 10, or 25 micrograms/kg)
Number of subjects: 17
Study: 1696418

Group type: EXPERIMENTAL
Intervention: Preparatory information with video film (n = 26)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preparatory information without video (n = 34)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preparatory information with video (n = 26)
Number of subjects: 60
Study: 7295489

Group type: EXPERIMENTAL
Intervention: Diacetolol 100 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diacetolol 200 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diacetolol 400 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diacetolol 800 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30173193

Group type: EXPERIMENTAL
Intervention: Camera-supervised OSCE
Number of subjects: 32

Group type: COMPARATOR
Intervention: Direct observation OSCE
Number of subjects: 32
Study: 26746199

Group type: EXPERIMENTAL
Intervention: Home-care F(−) treatment (FD) - 1,100 ppm F(−) dentifrice, 2x1 min/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Professional fluoride treatment (FVD) - 22,600 ppm F(−) varnish plus FD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C) - saliva
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TEMDP lesion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: General response to fluoride treatments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TMR measurements
Number of subjects: 12
Study: 24284438

Group type: EXPERIMENTAL
Intervention: Low-intensity behavioral intervention targeting gestational weight gain, healthy eating, and exercise (discontinued at delivery)
Number of subjects: 401
Study: 23796570

Group type: EXPERIMENTAL
Intervention: Intravesical pressure attenuation device
Number of subjects: 166

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 166
Study: 20152345

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (PD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Laparotomy (LAP)
Number of subjects: 69
Study: 18539672

Group type: EXPERIMENTAL
Intervention: Arthroscopically- and fluoroscopically-assisted reduction and external fixation plus percutaneous pinning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluoroscopically-assisted reduction alone and external fixation plus percutaneous pinning
Number of subjects: 20
Study: 16524439

Group type: EXPERIMENTAL
Intervention: Bronchial challenge with capsaicin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Severe symptoms to perfume (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21
Study: 15025702

Group type: EXPERIMENTAL
Intervention: Hand dishwashing liquid 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hand dishwashing liquid 2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Forearm immersion test
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact skin capacitance
Number of subjects: 30
Study: 11099368

Group type: EXPERIMENTAL
Intervention: Supplemental drink (SD; isocaloric and isonitrogenous to WF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole food (WF: protein 38 g; carbohydrate 70 g; fat 7 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate beverage (C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 10
Study: 8603220

Group type: EXPERIMENTAL
Intervention: 12% sucrose solution
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 285

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 285
Study: 1411702

Group type: EXPERIMENTAL
Intervention: High qualification with mention of disability
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Low qualification with mention of disability
Number of subjects: 2228

Group type: COMPARATOR
Intervention: High qualification without mention of disability
Number of subjects: 2228

Group type: COMPARATOR
Intervention: Low qualification without mention of disability
Number of subjects: 2228
Study: 3880819

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Netilmicin or Amikacin
Number of subjects: 3
Study: 31298158

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia
Number of subjects: 8000
Study: 30060746

Group type: EXPERIMENTAL
Intervention: Whole Grains (WG)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables (FV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (Refined Grains)
Number of subjects: 49
Study: 27088994

Group type: EXPERIMENTAL
Intervention: CSE with EVE of 10 mL normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSE NEVE
Number of subjects: 60
Study: 24219166

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone treatment for 12 weeks
Number of subjects: 360
Study: 21710292

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Contrast Water Immersion (CWT)
Number of subjects: 18
Study: 20167897

Group type: EXPERIMENTAL
Intervention: Experimental group 1 (specific intervention not detailed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Experimental group 2 (specific intervention not detailed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Experimental group 3 (specific intervention not detailed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Experimental group 1, 2, or 3 (specific intervention not detailed)
Number of subjects: 36
Study: 18401195

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation 3 times a week for 1 month, using a custom-made device generating direct and alternative current in 10-200 Hz frequency, with an amplitude of 50 to 2,000 mA and a pulse frequency of 30 Hz for 25 minutes per session.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo stimulation (no actual electrical stimulus given).
Number of subjects: 42
Study: 16085200

Group type: EXPERIMENTAL
Intervention: Repeated mailing of the questionnaire
Number of subjects: 955

Group type: COMPARATOR
Intervention: Simple reminder card
Number of subjects: 955

Group type: COMPARATOR
Intervention: Request to explain nonparticipation
Number of subjects: 955
Study: 12874583

Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Classic pancreatoduodenectomy (PD)
Number of subjects: 70
Study: 10472872

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 8567299

Group type: EXPERIMENTAL
Intervention: Fluid-filled circulating blanket (active-conductive external rewarming)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reflective blanket (passive-reflective external rewarming)
Number of subjects: 32
Study: 1784499

Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream applied 4 times/day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream (control) applied to the other forearm
Number of subjects: 0
Study: 6127542

Group type: EXPERIMENTAL
Intervention: microencapsulated potassium chloride formulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: wax-matrix formulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: glycopyrrolate
Number of subjects: 48
Study: 31623936

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (up to 2×3 mL)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard analgesic treatment
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 305
Study: 31292955

Group type: EXPERIMENTAL
Intervention: Fetal ultrasound biometry
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Fetal ultrasound measure
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Subscapular fat mass in the fetus and the newborn
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Abdominal fat mass (AFM) measurements
Number of subjects: 845
Study: 29079478

Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag intervention
Number of subjects: 633

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 633
Study: 26794137

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study: 25223711

Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice (PJ), 1.5 mL per kg body weight
Number of subjects: 85
Study: 22773261

Group type: EXPERIMENTAL
Intervention: C‐Leg (Otto Bock)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SNS (CaTech)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3R60 (Otto Bock)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C‐Leg (Otto Bock) with MLT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SNS (CaTech) with MLT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3R60 (Otto Bock) with MLT
Number of subjects: 12
Study: 20304867

Group type: EXPERIMENTAL
Intervention: High fibrinogen levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Elevated fibrinogen levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Elevated fibrinogen levels with angiographic progression or nonregression
Number of subjects: 111
Study: 18053393

Group type: EXPERIMENTAL
Intervention: Beta-blockers (atenolol 100 mg id for five consecutive days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 10
Study: 16075416

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simvastatin and Atorvastatin
Number of subjects: 60
Study: 12131435

Group type: EXPERIMENTAL
Intervention: Dynamic fixation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Static fixation
Number of subjects: 52
Study: 10229887

Group type: EXPERIMENTAL
Intervention: Peer Assessment Rating (PAR) index treatment
Number of subjects: 103
Study: 8561152

Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline 250 mg, metronidazole 250 mg, colloidal bismuth subcitrate 120 mg, four times daily for 14 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Amoxicillin (1000 mg) and omeprazole (40 mg) both twice daily for 14 days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Amoxicillin/omeprazole
Number of subjects: 118
Study: 1811640

Group type: EXPERIMENTAL
Intervention: Fittydent
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Super Poligrip
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Super Wernet's
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: tragacanth
Number of subjects: 32
Study: 6882885

Group type: EXPERIMENTAL
Intervention: Quinidine administered with food
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinidine administered with antacid
Number of subjects: 9

Group type: COMPARATOR
Intervention: Quinidine administered in fasting state
Number of subjects: 9
Study: 31175564

Group type: EXPERIMENTAL
Intervention: Adolescent family-centered intervention
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 463
Study: 29250772

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 26573488

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy for the prevention of hand eczema
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1649
Study: 25041789

Group type: EXPERIMENTAL
Intervention: Monitoring-plus-reinforcement-thinning condition
Number of subjects: 77

Group type: COMPARATOR
Intervention: Monitoring-only condition
Number of subjects: 77
Study: 22228043

Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No doxazosin (control group)
Number of subjects: 79
Study: 20368567

Group type: EXPERIMENTAL
Intervention: Rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone induction treatment
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: BCL2/IgH levels at the end of induction treatment
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Pretreatment positive BM results
Number of subjects: 465
Study: 17347577

Group type: EXPERIMENTAL
Intervention: Cellulosic membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study: 15736262

Group type: EXPERIMENTAL
Intervention: Inoue balloon (IB) technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metallic commissurotome (MC) technique
Number of subjects: 50
Study: 11862508

Group type: EXPERIMENTAL
Intervention: Soft diet recommended after bowel surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fiber diet
Number of subjects: 0
Study: 11277447

Group type: EXPERIMENTAL
Intervention: Fixed block condition (with both within- and across-trial variability information)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Partial-random condition (with within-trial variability information)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Full-random condition (with neither within- nor across-trial variability information)
Number of subjects: 3
Study: 9735662

Group type: EXPERIMENTAL
Intervention: Specific IgE (slgE) antibodies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Specific IgG4 (slgG4) antibodies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Specific IgG antibodies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Specific IgG4 antibodies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Exposure duration
Number of subjects: 42
Study: 8042449

Group type: EXPERIMENTAL
Intervention: Early surgical revision of the septic focus (Group 1, within 6 days, n = 15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Late surgery (Group 2, later than 6 days, n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No surgery at all (Group 3, n = 6)
Number of subjects: 40
Study: 2759066

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 0
Study: 1099048

Group type: EXPERIMENTAL
Intervention: Doctor's Choice (DC) method of administering psychotropic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thioridazine (100 to 900 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlordiazepoxide (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (75 mg)
Number of subjects: 0
Study: 396656

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 150 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study: 31210636

Group type: EXPERIMENTAL
Intervention: Survey of parents' knowledge and experiences with LVAS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Survey of audiologists' knowledge and experiences with LVAS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interest in continuing education about LVAS
Number of subjects: 100
Study: 29034602

Group type: EXPERIMENTAL
Intervention: Paracetamol alone (G-1)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combined Ibuprofen/Paracetamol (G-2)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combined Mefenamic acid/Paracetamol (G-3)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combined Diclofenac K/Paracetamol (G-4)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (G-5)
Number of subjects: 170
Study: 27317708

Group type: EXPERIMENTAL
Intervention: Comic information leaflet (delivered at home in addition to routine information)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Routine information only (control group)
Number of subjects: 115
Study: 24770560

Group type: EXPERIMENTAL
Intervention: Wireless, portable vital signs monitor (WVSM)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard monitor (control)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Both WVSM and standard monitor
Number of subjects: 305
Study: 22521148

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 20
Study: 20609991

Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conservative standard treatment (CST)
Number of subjects: 84
Study: 18047883

Group type: EXPERIMENTAL
Intervention: Diabetic blind subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nondiabetic blind subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Blindfolded sighted volunteers
Number of subjects: 29
Study: 16315646

Group type: EXPERIMENTAL
Intervention: Direct-likelihood methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete case analysis (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Last observation carried forward (LOCF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectation-maximization algorithm
Number of subjects: 0
Study: 12364427

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg Nutropin Depot
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Nutropin Depot
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Higher dose Nutropin Depot
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both doses Nutropin Depot
Number of subjects: 25
Study: 9923825

Group type: EXPERIMENTAL
Intervention: 300 mg hydroxyethylrutosiden given orally four times daily (group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No hydroxyethylrutosiden (group B)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 7793451

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg body weight per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25